Exploring how gut bacteria affect treatment outcomes in chronic myeloid leukemia patients
Interaction Between Gut Microbiota and Tyrosine Kinase Inhibitors in Defining the Clinical Outcomes of Patients With Chronic Myeloid Leukemia
This study is trying to see how gut bacteria might affect how well chronic myeloid leukemia patients respond to a specific cancer treatment called Tyrosine Kinase Inhibitors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Turin, Italy Academic / other |
| Locations | 1 site (Torino) |
| Trial ID | NCT06724536 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between gut microbiota and the effectiveness of Tyrosine Kinase Inhibitors (TKIs) in patients with Chronic Myeloid Leukemia (CML). It aims to identify specific microbial signatures that may correlate with better treatment responses, particularly in achieving deep molecular response (DMR). The study will analyze biological samples from CML patients to assess how variations in gut microbiota might influence treatment efficacy and contribute to side effects or metabolic disorders. By understanding these interactions, the research seeks to enhance patient outcomes and quality of life during TKI therapy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with Chronic Myeloid Leukemia, regardless of the disease stage.
Not a fit: Patients who do not have Chronic Myeloid Leukemia or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies that improve outcomes for CML patients by considering their gut microbiota.
How similar studies have performed: While the role of gut microbiota in cancer treatment is gaining attention, this specific investigation into its effects on CML outcomes with TKIs is novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years old * Chronic Myeloid Leukemia Patients * Any stage of the disease Exclusioni Criteria: none
Where this trial is running
Torino
- AO Ordine Mauriziano di Torino — Torino, Italy (Recruiting)
Study contacts
- Principal investigator: Carmen Fava — Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
- Study coordinator: Carmen Fava
- Email: carmen.fava@unito.it
- Phone: 00390115082224
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.